Compare Abeona Therapeutics Inc (ABEO) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ross Stores, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.62 (market cap $424.33M), while Ross Stores, Inc. trades at $252 (market cap $81.74B). The key difference: Ross Stores, Inc. is far larger — about 192.6× Abeona Therapeutics Inc's market cap, and Ross Stores, Inc. pays a 0.7% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ROST | |
|---|---|---|
Market Cap | $424.33M | $81.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $255.23 |
52-Week Low | $4.17 | $144.67 |
Enterprise Value | $279.23M | $82.34B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Ross Stores (ROST) trades at $255.23, up 0.36% on the day, near its consensus price target of $259. The stock shows strong momentum with a bullish technical signal and consistent earnings beats, including Q1 2026 EPS of $2.02 versus $1.73 expected. Revenue growth accelerated to $21.13B in 2025, with net income margin improving to 9.74%. Recent expansion includes 47 new stores opened in June-July 2026, supporting future growth.
Outlook remains positive given robust fundamentals and analyst optimism, but valuation multiples like P/E of 35.65 suggest premium pricing. Key risks include consumer spending sensitivity and competitive pressures in discount retail. The stock offers growth potential with disciplined execution, though investors should weigh high valuation against earnings sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
